Intra-Cellular (ITCI) | Stock Overview & Key Data
Intra-Cellular Performance Comparison
Stock Range
Today's Range
Low: $131.87
High: $131.87
on June 20, 2025
52 Week Range
Low: $64.09
High: $131.98
on May 20, 2024
on April 1, 2025
All-Time High: $131.98 on March 31, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$14.0B
EPS
-0.73
P/E Ratio (TTM)
-183.15
Forward P/E
507.19
P/B Ratio
12.20
PEG Ratio
507.19
Div. Yield
N/A
ROE
-8.58%
Beta
0.462
Debt to Equity
1.48
Financial Highlights
Profitability
Gross Margin
89.76%
Operating Margin
-14.66%
Profit Margin
-10.97%
Returns and Earnings
Return on Assets (TTM)
-6.96%
Return on Equity (TTM)
-8.58%
EBITDA
$-116.2M
Net Income (TTM)
$-74.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$6.41
Quarterly Revenue Growth (YoY)
50.80%
Quarterly Earnings Growth (YoY)
51.49%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Intra-Cellular ITCI | 14.05B Large-cap | 0.14% | 0.45% | 56.54% | 81.59% | 56.54% | 92.68% | 104.13% | 700.67% |
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 43.62B Large-cap | 1.15% | -0.82% | -9.56% | -3.40% | 2.22% | -0.31% | 61.37% | 30.23% |
| United Therapeutics UTHR | 13.63B Large-cap | 3.86% | 6.78% | 3.03% | -16.01% | -13.07% | -2.45% | 39.52% | 191.96% |
| Neurocrine NBIX | 13.05B Large-cap | 6.31% | 1.26% | 10.50% | 16.61% | -3.60% | -8.35% | 24.21% | 17.50% |
| Viatris VTRS | 12.46B Large-cap | 9.38% | 18.81% | 20.71% | -2.30% | -14.57% | -9.01% | 0.38% | -33.65% |
Ownership & Short Interest
Insider Ownership
2.48%
Institutional Ownership
96.45%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Intra-Cellular Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Intra-Cellular would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ITCI's 52-week high and low?
- In the last 52 weeks, Intra-Cellular reached a high of $131.98 (on April 1, 2025) and a low of $64.09 (on May 20, 2024).
- What is the market cap and P/E ratio for ITCI?
- Curious about Intra-Cellular's size and valuation? Its market capitalization stands at 14.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is -183.15, and the forward P/E (looking ahead) is 507.19.
- Does ITCI pay dividends? If so, what's the yield?
- As for dividends, Intra-Cellular isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Intra-Cellular's main competitors or similar companies to consider before investing?
When looking at Intra-Cellular, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -16.11% -9.09% Haleon Plc - ADR
HLN43.62B Healthcare Drug Manufacturers - Specialty & Generic -0.31% 61.37% United Therapeutics
UTHR13.63B Healthcare Drug Manufacturers - Specialty & Generic -2.45% 39.52% Neurocrine
NBIX13.05B Healthcare Drug Manufacturers - Specialty & Generic -8.35% 24.21% Viatris
VTRS12.46B Healthcare Drug Manufacturers - Specialty & Generic -9.01% 0.38% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Intra-Cellular Therapies Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Intra-Cellular's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -8.58%, the Debt to Equity ratio from the most recent quarter is 1.48, and its Gross Profit Margin stands at 89.76%.
- What is the recent revenue and earnings growth for ITCI?
- Looking at Intra-Cellular's growth, its revenue over the trailing twelve months (TTM) was $681M. Compared to the same quarter last year (YoY), quarterly revenue grew by 50.80%, and quarterly earnings saw a YoY growth of 51.49%.
- How much of ITCI stock is held by insiders and institutions?
- Wondering who owns Intra-Cellular stock? Company insiders (like executives and directors) hold about 2.48% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.45%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.